Trial reportDiabetologia1996
Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.
Trial report in Diabetologia, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.Clinics (Sao Paulo, Brazil) · 2012Trial
- Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.British journal of clinical pharmacology · 2003Trial
- In vivo evidence for K(Ca) channel opening properties of acetazolamide in the human vasculature.British journal of pharmacology · 2001Trial
- A simulation study on the antiarrhythmic mechanisms of established agents in myocardial ischemia and infarction.PLoS computational biology · 2024Article
- Effect of glucose-lowering therapies on heart failure.Nature reviews. Cardiology · 2018Review
- Metabolomic analysis of healthy human urine following administration of glimepiride using a liquid chromatography-tandem mass spectrometry.Translational and clinical pharmacology · 2017Article
- Acute inhibition of ATP-sensitive K+ channels impairs skeletal muscle vascular control in rats during treadmill exercise.American journal of physiology. Heart and circulatory physiology · 2015Article
- Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.Diabetes, metabolic syndrome and obesity : targets and therapy · 2012Article
- A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.Vascular health and risk management · 2007Review
- Do sulfonylurea drugs increase the risk of cardiac events?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2006Article
- Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.Journal of endocrinological investigation · 2004Review
- ATP-induced vasodilation in human skeletal muscle.British journal of pharmacology · 2004Article
- Sulphonylurea action revisited: the post-cloning era.Diabetologia · 2003Review
- Review
- Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease.Heart (British Cardiac Society) · 2002Article
- Comparative tolerability of sulphonylureas in diabetes mellitus.Drug safety · 2000Review
- Review
- Is there a concentration-effect relationship for sulphonylureas?Clinical pharmacokinetics · 1998Review
- Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?Diabetologia · 1996Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular adenosine-5'-triphosphate-sensitive potassium (KATP) channels have been reported to play an important role in endogenous cardioprotective mechanisms. Sulphonylurea derivatives can inhibit these cardioprotective mechanisms in animal models. We investigated whether therapeutic concentrations of sulphonylurea derivatives can block vascular KATP channels in humans. The forearm vasodilator responses to administration of the specific KATP channel opener diazoxide into the brachial artery of healthy male volunteers were recorded by venous occlusion plethysmography. This procedure was repeated with concomitant intraarterial infusion of:1) the sulphonylurea derivative glibenclamide (0.33 or 3.3 micrograms. min-1. dl-1, both n = 12), 2) the new sulphonylurea derivative glimepiride (2.5 micrograms.min-1. dl-1, n = 12) or 3) placebo (n = 12). The effects of glibenclamide on the vasodilator responses to sodium nitroprusside were also studied (n = 12). Glibenclamide significantly inhibited the diazoxide-induced increase in forearm blood flow ratio (ANOVA with repeated measures: p < 0.01). During the highest diazoxide dose this ratio (mean +/- SEM) was lowered from 892 +/- 165 to 449 +/- 105%, and from 1044 +/- 248 to 663 +/- 114% by low- and high-dose glibenclamide, respectively. In contrast, neither glimepiride nor placebo attenuate diazoxide-induced vasodilation. Furthermore, glibenclamide did not affect nitroprusside-induced vasodilation. We conclude that therapeutic concentrations of the classical sulphonylurea derivative glibenclamide result in significant blockade of vascular KATP channels in humans. The newly developed glimepiride seems to be devoid of these properties.
Indexed as
Identifiers
8877293What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.